CVE:PBS

Pacgen Life Science Co. (PBS.V) Competitors

C$0.03
+0.01 (+20.00 %)
(As of 09/16/2020)
Add
Compare
Today's Range
C$0.03
Now: C$0.03
C$0.03
50-Day Range
C$0.03
MA: C$0.03
C$0.03
52-Week Range
C$0.01
Now: C$0.03
C$0.05
Volume2,000 shs
Average Volume63,601 shs
Market CapitalizationC$1.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pacgen Life Science Co. (PBS.V) (CVE:PBS) Vs. BCT, RVV, COT, MFS, CHV, and PREV

Should you be buying PBS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Pacgen Life Science Co. (PBS.V), including BriaCell Therapeutics (BCT), Revive Therapeutics (RVV), Cotinga Pharmaceuticals Inc. (COT.V) (COT), Medifocus Inc. (MFS.V) (MFS), (CHV) (CHV), and (PREV) (PREV).

Pacgen Life Science Co. (PBS.V) (CVE:PBS) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Pacgen Life Science Co. (PBS.V) and BriaCell Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacgen Life Science Co. (PBS.V)0000N/A
BriaCell Therapeutics0000N/A

Valuation and Earnings

This table compares Pacgen Life Science Co. (PBS.V) and BriaCell Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacgen Life Science Co. (PBS.V)C$302,079.006.44C$-388,896.00C($0.01)-5.00
BriaCell TherapeuticsN/AN/AN/AC($3.10)-1.17

BriaCell Therapeutics has lower revenue, but higher earnings than Pacgen Life Science Co. (PBS.V). Pacgen Life Science Co. (PBS.V) is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacgen Life Science Co. (PBS.V) and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacgen Life Science Co. (PBS.V)N/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Summary

Pacgen Life Science Co. (PBS.V) beats BriaCell Therapeutics on 2 of the 3 factors compared between the two stocks.

Pacgen Life Science Co. (PBS.V) (CVE:PBS) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares Pacgen Life Science Co. (PBS.V) and Revive Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacgen Life Science Co. (PBS.V)C$302,079.006.44C$-388,896.00C($0.01)-5.00
Revive TherapeuticsN/AN/AN/AC($0.02)-3.64

Revive Therapeutics has lower revenue, but higher earnings than Pacgen Life Science Co. (PBS.V). Pacgen Life Science Co. (PBS.V) is trading at a lower price-to-earnings ratio than Revive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Pacgen Life Science Co. (PBS.V) and Revive Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacgen Life Science Co. (PBS.V)0000N/A
Revive Therapeutics0000N/A

Profitability

This table compares Pacgen Life Science Co. (PBS.V) and Revive Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacgen Life Science Co. (PBS.V)N/AN/AN/A
Revive TherapeuticsN/AN/AN/A

Summary

Pacgen Life Science Co. (PBS.V) beats Revive Therapeutics on 2 of the 3 factors compared between the two stocks.

Cotinga Pharmaceuticals Inc. (COT.V) (CVE:COT) and Pacgen Life Science Co. (PBS.V) (CVE:PBS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares Cotinga Pharmaceuticals Inc. (COT.V) and Pacgen Life Science Co. (PBS.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cotinga Pharmaceuticals Inc. (COT.V)N/AN/AN/A
Pacgen Life Science Co. (PBS.V)N/AN/AN/A

Earnings and Valuation

This table compares Cotinga Pharmaceuticals Inc. (COT.V) and Pacgen Life Science Co. (PBS.V)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cotinga Pharmaceuticals Inc. (COT.V)N/AN/AN/AC($0.12)-0.30
Pacgen Life Science Co. (PBS.V)C$302,079.006.44C$-388,896.00C($0.01)-5.00

Cotinga Pharmaceuticals Inc. (COT.V) has higher earnings, but lower revenue than Pacgen Life Science Co. (PBS.V). Pacgen Life Science Co. (PBS.V) is trading at a lower price-to-earnings ratio than Cotinga Pharmaceuticals Inc. (COT.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cotinga Pharmaceuticals Inc. (COT.V) and Pacgen Life Science Co. (PBS.V), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cotinga Pharmaceuticals Inc. (COT.V)0000N/A
Pacgen Life Science Co. (PBS.V)0000N/A

Dividends

Cotinga Pharmaceuticals Inc. (COT.V) pays an annual dividend of C$0.24 per share and has a dividend yield of 685.7%. Pacgen Life Science Co. (PBS.V) pays an annual dividend of C$0.09 per share and has a dividend yield of 300.0%. Cotinga Pharmaceuticals Inc. (COT.V) pays out -208.7% of its earnings in the form of a dividend. Pacgen Life Science Co. (PBS.V) pays out -1,500.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Pacgen Life Science Co. (PBS.V) beats Cotinga Pharmaceuticals Inc. (COT.V) on 3 of the 5 factors compared between the two stocks.

Medifocus Inc. (MFS.V) (CVE:MFS) and Pacgen Life Science Co. (PBS.V) (CVE:PBS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Medifocus Inc. (MFS.V) and Pacgen Life Science Co. (PBS.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medifocus Inc. (MFS.V)N/AN/AN/A
Pacgen Life Science Co. (PBS.V)N/AN/AN/A

Valuation and Earnings

This table compares Medifocus Inc. (MFS.V) and Pacgen Life Science Co. (PBS.V)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifocus Inc. (MFS.V)C$2.23 million0.83C$-1,849,840.00C($0.01)-1.00
Pacgen Life Science Co. (PBS.V)C$302,079.006.44C$-388,896.00C($0.01)-5.00

Pacgen Life Science Co. (PBS.V) has lower revenue, but higher earnings than Medifocus Inc. (MFS.V). Pacgen Life Science Co. (PBS.V) is trading at a lower price-to-earnings ratio than Medifocus Inc. (MFS.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Medifocus Inc. (MFS.V) and Pacgen Life Science Co. (PBS.V), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medifocus Inc. (MFS.V)0000N/A
Pacgen Life Science Co. (PBS.V)0000N/A

Summary

Pacgen Life Science Co. (PBS.V) beats Medifocus Inc. (MFS.V) on 3 of the 5 factors compared between the two stocks.

(CHV) (CNSX:CHV) and Pacgen Life Science Co. (PBS.V) (CVE:PBS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Profitability

This table compares (CHV) and Pacgen Life Science Co. (PBS.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(CHV)N/AN/AN/A
Pacgen Life Science Co. (PBS.V)N/AN/AN/A

Valuation & Earnings

This table compares (CHV) and Pacgen Life Science Co. (PBS.V)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(CHV)N/AN/AN/AN/AN/A
Pacgen Life Science Co. (PBS.V)C$302,079.006.44C$-388,896.00C($0.01)-5.00

(CHV) has higher earnings, but lower revenue than Pacgen Life Science Co. (PBS.V).

Analyst Ratings

This is a summary of recent recommendations and price targets for (CHV) and Pacgen Life Science Co. (PBS.V), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(CHV)0000N/A
Pacgen Life Science Co. (PBS.V)0000N/A

Summary

Pacgen Life Science Co. (PBS.V) beats (CHV) on 1 of the 1 factors compared between the two stocks.

(PREV) (CNSX:PREV) and Pacgen Life Science Co. (PBS.V) (CVE:PBS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for (PREV) and Pacgen Life Science Co. (PBS.V), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(PREV)0000N/A
Pacgen Life Science Co. (PBS.V)0000N/A

Valuation and Earnings

This table compares (PREV) and Pacgen Life Science Co. (PBS.V)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(PREV)N/AN/AN/AN/AN/A
Pacgen Life Science Co. (PBS.V)C$302,079.006.44C$-388,896.00C($0.01)-5.00

(PREV) has higher earnings, but lower revenue than Pacgen Life Science Co. (PBS.V).

Profitability

This table compares (PREV) and Pacgen Life Science Co. (PBS.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(PREV)N/AN/AN/A
Pacgen Life Science Co. (PBS.V)N/AN/AN/A

Summary

Pacgen Life Science Co. (PBS.V) beats (PREV) on 1 of the 1 factors compared between the two stocks.


Pacgen Life Science Co. (PBS.V) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BCT
BriaCell Therapeutics
0.5$3.61+5.8%C$4.48 millionN/A-1.17
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.93+1.3%C$0.00C$267.59 million51.57
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00News Coverage
Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.